Press Releases
GI Dynamics Announces Close of US$1.75 M Convertible Note and Warrant Financing from Crystal Amber
BOSTON and SYDNEY – 31 May 2018 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to confirm that, further to the Company’s announcement on 2 May 2018, it has completed the US$1,750,000 convertible note...
read moreGI Dynamics Announces Access to 2018 Annual Meeting of Stockholders and Corporate Update
BOSTON and SYDNEY — 16 May 2018 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2018 Annual Meeting of Stockholders on 24 May 2018 at 6:00 pm United States Eastern Daylight Time, (which is 25 May 2018 at 8:00 am Australian Eastern Standard Time), at the offices of Mintz, Levin, Cohn,...
read moreEndoBarrier Meta-Analysis Published in Diabetes Care Journal
BOSTON and SYDNEY – 10 May 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic...
read moreGI Dynamics Announces US$1.75M Convertible Note and Warrant Financing Commitment from Crystal Amber Fund Subject to Obtaining Stockholder Approval
BOSTON and SYDNEY – 2 May 2018 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has received a binding commitment for a US$1,750,000 convertible note and warrant financing from Crystal Amber Fund Limited. The...
read moreGI Dynamics to Release 2017 Annual Report and Host Shareholder Update Call for Year End Results
BOSTON and SYDNEY – 28 March 2018 – GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announced that it will release its 2017 Annual Report on Form 10K on or before 31 March EDT | 1 April AEST 2018. GI Dynamics...
read moreGI Dynamics Announces Close of Second Tranche of Placement – AUD ~$1m
BOSTON and SYDNEY — 8 March 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has today successfully completed the second tranche of the Placement (as detailed further in the 23 January 2018 announcement). The closing of...
read moreGI Dynamics, Inc. Announces Results of Adjourned Special Meeting
BOSTON and SYDNEY — 28 February 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier®, held an adjourned Special Meeting on Tuesday, 27 February 2018 at 3:00pm Eastern Standard Time (being Wednesday, 28 February 2018 at 7:00am Australian Eastern Daylight...
read moreGI Dynamics Announces Details of Special Meeting of the Company’s Stockholders
BOSTON and SYDNEY — 07 February 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to confirm that, further to its announcement released on 23 January 2018, the attached proxy statement and notice of a special meeting of stockholders (Special...
read moreGI Dynamics Announces AUD $2.05m Private Placement and Close of First Tranche of AUD ~$1m
BOSTON and SYDNEY — 23 January 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has received binding commitments for a private placement of 58,780,619 CHESS Depositary Interests (CDIs) of the Company (representing 1,175,612...
read moreGI Dynamics, Inc. Provides 2017 Review And 2018 Business Outlook
BOSTON and SYDNEY — 15 January 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® provides shareholders with a review of 2017 activities and its 2018 business outlook. GI Dynamics is preparing to submit an Investigational Device Exemption (IDE[1])...
read more